CLINICAL_TRIALS
trial_result
· 2021-07-02
Clinical Trial Update: A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia [Phase 2]
Summary
Phase 2 dose optimisation study of ASLAN003 in acute myeloid leukemia completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ASLAN Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-07-02